SYRE — Spyre Therapeutics Share Price
Last trade - 00:00Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 7.73 | ||
| Price to Tang. Book | 7.73 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -18.14% | ||
| Return on Equity | -28.31% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2021 | 2022 | 2023 | 2024 | 2025 | 2026E | 2027E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 18.74 | 2.33 | 0.89 | n/a | n/a | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Spyre Therapeutics, Inc. is a clinical-stage biotechnology company, specializing in long-acting antibodies and antibody combinations for inflammatory bowel disease (IBD) and rheumatic diseases. The Company's pipeline includes investigational extended half-life antibodies targeting a4b7, TL1A, and IL-23. It is advancing a pipeline of monoclonal antibodies (mAbs) for the treatment of IBD and other immune-mediated diseases. The Company's pipeline includes its SKYLINE Phase II platform trial evaluating SPY001, SPY002, SPY003, and pairwise combinations thereof in subjects with moderately to severely active UC and its SKYWAY basket trial evaluating SPY072 in three rheumatic diseases: rheumatoid arthritis (RA), psoriatic arthritis (PsA), and axial spondyloarthritis (axSpA). SPY001 is a highly potent, highly selective, and humanized monoclonal immunoglobulin G1 investigational antibody designed to bind selectively to the a4b7 integrin being developed for the treatment of IBD (UC and CD).
Directors
- Russell Cox NEC (57)
- Anthony Quinn PRE (59)
- Jonathan Alspaugh CFO (38)
- Leslie Sloan COO (50)
- Steven Weber VPR (44)
- Jim Kastenmayer GCN (49)
- Michael Hanley OTH (48)
- Hunter Smith DRC (53)
- Marcio Souza DRC (42)
- V. Bryan Lawlis IND (69)
- Alison Lawton IND (60)
- Ivana Magovcevic-Liebisch IND
- Sandesh Mahatme IND (56)
- Armen Shanafelt IND (61)
- Last Annual
- December 31st, 2025
- Last Interim
- June 30th, 2026
- Incorporated
- December 16th, 2013
- Public Since
- April 7th, 2016
- No. of Shareholders
- 24
- No. of Employees
- 125
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Global Select Market
- Shares in Issue
- 92,181,781
- Address
- 221 Crescent Street, Suite 105, WALTHAM, 02453
- Web
- https://spyre.com/
- Phone
- +1 6176515940
- Contact
- Eric Mcintyre
- Auditors
- PricewaterhouseCoopers LLP
Latest News for SYRE
Upcoming Events for SYRE
Q3 2026 Spyre Therapeutics Inc Earnings Release
Q4 2026 Spyre Therapeutics Inc Earnings Release
Similar to SYRE
4D Molecular Therapeutics
NASDAQ Global Select Market
Aardvark Therapeutics
NASDAQ Global Select Market
AbCellera Biologics
NASDAQ Global Select Market
AbSci
NASDAQ Global Select Market
Acadia Pharmaceuticals
NASDAQ Global Select Market
FAQ
As of Today at 05:28 UTC, shares in Spyre Therapeutics are trading at $80.10. This share price information is delayed by 15 minutes.
Shares in Spyre Therapeutics last closed at $80.10 and the price had moved by +260.97% over the past 365 days. In terms of relative price strength the Spyre Therapeutics share price has outperformed the S&P500 Index by +209% over the past year.
The overall consensus recommendation for Spyre Therapeutics is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreSpyre Therapeutics does not currently pay a dividend.
Spyre Therapeutics does not currently pay a dividend.
Spyre Therapeutics does not currently pay a dividend.
To buy shares in Spyre Therapeutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $80.10, shares in Spyre Therapeutics had a market capitalisation of $7.38bn.
Here are the trading details for Spyre Therapeutics:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: SYRE
Based on an overall assessment of its quality, value and momentum Spyre Therapeutics is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Spyre Therapeutics is $120.69. That is 50.67% above the last closing price of $80.10.
Analysts covering Spyre Therapeutics currently have a consensus Earnings Per Share (EPS) forecast of -$2.71 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Spyre Therapeutics. Over the past six months, its share price has outperformed the S&P500 Index by +0.72%.
As of the last closing price of $80.10, shares in Spyre Therapeutics were trading +14.67% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Spyre Therapeutics PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $80.10.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Spyre Therapeutics' management team is headed by:
- Russell Cox - NEC
- Anthony Quinn - PRE
- Jonathan Alspaugh - CFO
- Leslie Sloan - COO
- Steven Weber - VPR
- Jim Kastenmayer - GCN
- Michael Hanley - OTH
- Hunter Smith - DRC
- Marcio Souza - DRC
- V. Bryan Lawlis - IND
- Alison Lawton - IND
- Ivana Magovcevic-Liebisch - IND
- Sandesh Mahatme - IND
- Armen Shanafelt - IND